Blog
Why Cybersecurity Has Become a Regulatory Priority
As combination products increasingly rely on software, connectivity, and digital interfaces, cybersecurity has moved from a secondary concern to a core regulatory expectation. What was once viewed as an IT or infrastructure issue is now clearly framed by regulators as a patient safety risk.
Vulnerabilities that go unaddressed during development can expose patient data, disrupt device performance, or create pathways into broader healthcare networks. FDA scrutiny has followed this reality—with expectations now focused on how cybersecurity risks are identified and controlled across the entire product lifecycle.
When Software Expands the Regulatory Scope
Once software plays a role in device operation, data handling, or clinical functionality, it introduces a new regulatory dimension. IEC 62304 establishes expectations for managing medical device software throughout its lifecycle, and FDA increasingly looks for evidence that these principles are embedded into development practices.
This includes clearly defining software architecture, understanding how different components interact, and documenting how risks are assessed and mitigated. Software complexity, especially when multiple operating systems, programming languages, or third-party components are involved, increases the likelihood that vulnerabilities exist. Regulators expect sponsors to demonstrate awareness of that complexity and control over its impact.
Secure by Design Starts at the Requirements Level
One of the most common contributors to cybersecurity weaknesses is poor design planning. When security requirements are vague, incomplete, or added late in development, vulnerabilities are often baked into the product.
FDA expectations increasingly reflect a “secure by design” mindset. The strongest cybersecurity controls are those that eliminate or reduce vulnerabilities through planned architecture and clear requirements. Protective mechanisms that detect and respond to threats are the next layer of defense.
Effective cybersecurity requires giving security considerations a formal seat at the design table, supported by subject matter expertise and documented decision-making. Otherwise, designers run the risk of relying primarily on labeling, instructions, or user warnings for security—which are considered the weakest mechanisms available.
Software Changes Are Lifecycle Events, Not IT Tasks
As vulnerabilities evolve, software must be maintained through updates and patches. These activities are not routine maintenance tasks. Each change has the potential to affect safety, performance, and compliance.
FDA expects organizations to assess software changes through a quality and risk lens, not an IT convenience lens. Updates tied to cybersecurity posture or device behavior typically require formal change control, risk evaluation, and verification. Organizations that lack clear criteria for distinguishing between design-controlled changes and minor maintenance should expect to struggle when questioned during inspections.
Cybersecurity Documentation FDA Now Expects
Cybersecurity reviews increasingly include specific deliverables that demonstrate transparency and control. One example is the Software Bill of Materials, which identifies third-party software components and dependencies. This allows regulators to assess supply chain risk and vulnerability exposure.
Threat modeling documentation is also becoming more common, showing how potential attack scenarios were identified and addressed. Additional artifacts may include secure development lifecycle procedures, vulnerability management processes, and post-market monitoring strategies that demonstrate ongoing accountability rather than one-time compliance.
Integrating Cybersecurity Into a Streamlined QMS
For combination products, cybersecurity controls can be integrated into an existing pharmaceutical quality system through the streamlined approach allowed under 21 CFR Part 4. This avoids duplicative systems while ensuring software and cybersecurity risks are appropriately governed.
Successful integration depends on alignment between software development, Design Controls, risk management, and quality oversight. When cybersecurity is embedded into the QMS and the D&D file for the device rather than bolted on after the fact, inspection readiness improves significantly.
How RCA Supports Software and Cybersecurity Readiness
Regulatory Compliance Associates® (RCA) helps life sciences organizations build inspection-ready software and cybersecurity frameworks tailored to combination products.
From TIR57 and ISO 14971 compliance and cybersecurity documentation to inspection preparation and training, RCA partners with teams to navigate this complex and rapidly evolving regulatory landscape with confidence.
Ready to streamline your QMS for combination product success?
Contact RCA today to schedule a consultation and take the first step toward regulatory readiness and market leadership.
